Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease.
JACC Basic Transl Sci
; 5(9): 916-927, 2020 Sep.
Article
em En
| MEDLINE
| ID: mdl-33015414
ABSTRACT
Mice with obesity and metabolic heart disease (MHD) due to a high-fat, high-sucrose diet were treated with placebo, a clinically relevant dose of sacubitril (SAC)/valsartan (VAL), or an equivalent dose of VAL for 4 months. There were striking differences between SAC/VAL and VAL with regard to 1) diastolic dysfunction; 2) interstitial fibrosis; and to a lesser degree; 3) oxidative stress-all of which were more favorably affected by SAC/VAL. SAC/VAL and VAL similarly attenuated myocardial hypertrophy and improved myocardial energetics. In mice with obesity-related MHD, neprilysin inhibition exerts favorable effects on diastolic function.
ARB, angiotensin receptor blocker; ATP, adenosine triphosphate; CD, control diet; GMP, guanosine monophosphate; HFHS, high-fat, high-sucrose; HFpEF, heart failure with a preserved ejection fraction; LV, left ventricular; MHD, metabolic heart disease; MNA, methoxy-2-naphthlamine; NMR, nuclear magnetic resonance; PCr, phosphocreatine; ROS, reactive oxygen species; RPP, rate × pressure product; SAC/VAL, sacubitril/valsartan; VAL, valsartan; diastolic; neprilysin; obesity
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
Idioma:
En
Revista:
JACC Basic Transl Sci
Ano de publicação:
2020
Tipo de documento:
Article